Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements Clinical Trials

9 clinical trials for Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma — RECRUITING · PHASE2
• Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma — RECRUITING · PHASE1
• Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma — RECRUITING · PHASE1
• Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma — ACTIVE_NOT_RECRUITING · PHASE2
• Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas — ACTIVE_NOT_RECRUITING · PHASE2
• TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma — ACTIVE_NOT_RECRUITING · PHASE2
• Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma — ACTIVE_NOT_RECRUITING · PHASE2
• huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia — TERMINATED · PHASE1
• JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma — TERMINATED · PHASE1

Refine this search